AbbVie Inc. is a U.S.-based biopharmaceutical company operating in the Healthcare sector. It focuses on the research, development, and commercialization of innovative medicines. Its shares are traded on the New York Stock Exchange under the ticker ABBV.

AbbVie develops therapies for complex and chronic conditions across multiple therapeutic areas, including:

• Immunology: Treatments for autoimmune diseases.

• Oncology: Cancer therapies targeting various tumor types.

• Neuroscience: Medicines for neurological and psychiatric disorders.

• Aesthetics and Specialty Care: Products in medical aesthetics and related fields.

The company generates revenue from a diversified portfolio of biologic and small-molecule therapies and continues to invest heavily in research and development to strengthen its pipeline.

AbbVie operates globally, with commercial, research, and manufacturing facilities across North America, Europe, Asia, and other regions.

History and Development

AbbVie was established in the early 2010s as a spin-off from Abbott Laboratories, allowing it to focus exclusively on innovative biopharmaceutical products.

In its initial years, growth was driven by strong performance in immunology treatments. Over time, the company pursued strategic acquisitions to diversify its portfolio and reduce dependence on individual products.

A major expansion occurred with the acquisition of Allergan, which broadened AbbVie’s presence in aesthetics and neuroscience.

In recent years, AbbVie has focused on expanding its pipeline in oncology, immunology, and neuroscience while addressing patent cycles through product diversification and innovation.

Today, AbbVie remains a major global biopharmaceutical company, centered on advanced therapies and long-term research-driven growth.

Additional Information

AbbVie Inc. (United States) is listed on the NYSE and has a market capitalization of $503.53 billion, with shareholders equity totaling $-5.94 billion.

The company employs approximately 47.000 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, AbbVie Inc. reported $64.39 billion in revenue, generating net income of $6.32 billion.

Key financial metrics include a P/E ratio of 79.71, a price-to-book (P/B) ratio of -84.84, and a trailing twelve-month dividend yield of 2.40%.

The company trades under the ticker ABBV.